- Home
- BCLI vs KPRX Comparison
BCLI vs KPRX Comparison
Compare BCLI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- KPRX
- Stock Information
- Founded
- BCLI 2000
- KPRX 1998
- Country
- BCLI United States
- KPRX United States
- Employees
- BCLI N/A
- KPRX N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BCLI Health Care
- KPRX Health Care
- Exchange
- BCLI Nasdaq
- KPRX Nasdaq
- Market Cap
- BCLI 7.7M
- KPRX 9.1M
- IPO Year
- BCLI N/A
- KPRX N/A
- Fundamental
- Price
- BCLI $1.22
- KPRX $3.08
- Analyst Decision
- BCLI Strong Buy
- KPRX Strong Buy
- Analyst Count
- BCLI 1
- KPRX 1
- Target Price
- BCLI $30.00
- KPRX $10.00
- AVG Volume (30 Days)
- BCLI 3.4M
- KPRX 1.3M
- Earning Date
- BCLI 05-15-2025
- KPRX 05-09-2025
- Dividend Yield
- BCLI N/A
- KPRX N/A
- EPS Growth
- BCLI N/A
- KPRX N/A
- EPS
- BCLI N/A
- KPRX N/A
- Revenue
- BCLI N/A
- KPRX $20,000.00
- Revenue This Year
- BCLI N/A
- KPRX N/A
- Revenue Next Year
- BCLI N/A
- KPRX N/A
- P/E Ratio
- BCLI N/A
- KPRX N/A
- Revenue Growth
- BCLI N/A
- KPRX N/A
- 52 Week Low
- BCLI $0.72
- KPRX $2.51
- 52 Week High
- BCLI $8.09
- KPRX $5.55
- Technical
- Relative Strength Index (RSI)
- BCLI 55.90
- KPRX 48.79
- Support Level
- BCLI $1.05
- KPRX $2.90
- Resistance Level
- BCLI $1.18
- KPRX $4.18
- Average True Range (ATR)
- BCLI 0.14
- KPRX 0.26
- MACD
- BCLI 0.00
- KPRX 0.00
- Stochastic Oscillator
- BCLI 23.91
- KPRX 19.12
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.